Study

Population

Country

Name of vaccine

Clinical
stage

Trial number

Blinding

NO of
vaccinated

Controls

Asano 2021

18-55;56-60;≥70y

Japan

ChAdOx1 nCoV-19

Ⅰ/Ⅱ

NCT04568031

Double

192

65

Chappel 2021

18-55y

Australia

Sclamp

Ⅰ

NCT04495933

Double

98

22

Chu 2021

18-55y；
＞56y

United States

mRNA-1273

Ⅱ

NCT04405076

Double

400

200

Clemens 2021

18-55;56-60;≥70y

Brazil

ChAdOx1 nCoV-19

Ⅲ

ISRCTN89951424

Unblinded

4772

4661

Emary 2021

>18y

United Kingdom

ChAdOx1 nCoV-19

Ⅱ/Ⅲ

NCT04400838

Single

4244

4290

Fadlyana 2021

18-59y

Indonesia

CoronaVac

Ⅲ

NCT04508075

Double

810

810

Formica 2021

18-59y；60-84y

Australia;
United States

NVX-CoV2373

Ⅱ

NCT04368988

Double

1032

257

Frenck 2021

12-15/16-25y

United States

BNT162b2

Ⅲ

NCT04368728

Double

3009

3043

Guo 2021

18-59y； ≥60y

China

Vero Cell

Ⅰ/Ⅱ

ChiCTR2000031809

Double

826

294

Han 2021

3-17y

China

CoronaVac

Ⅰ/Ⅱ

NCT04551547

Double

438

114

Hsieh 2021

20-64； ≥65

Taiwan, China

MVC-COV1901

Ⅱ

NCT04695652

Double

3304

550

Kaabi 2021

＞18y

United Arab Emirates; Bahrain

WIV04/HB02

Ⅲ

NCT04510207

Double

26936

13471

Kremsner
2021

18-60y; ≥61y

Germany;   Belgium;Argentina,et al

CVnCoV

Ⅱ/Ⅲ

NCT04652102

Single

2003

1978

Li  2021

18-55；65-85

China

BNT162b1

Ⅰ

NCT04523571

Double

96

48

Logunov 2021

＞18y

Russia

rAd26/rAd5

Ⅲ

NCT04530396

Double

16501

5476

Madhi 2021

18-65y

South Africa

ChAdOx1 nCoV-19

Ⅰ/Ⅱ

NCT04444674

Double

81

79

Meng 2021

18-55y； ＞56y

China

Sf9 cells

Ⅰ/Ⅱ

NCT04640402

Double

925

202

Munro 2021

≥30y

United Kingdom

ChAdOx1
nCov-19/BNT162b2

Ⅱ

ISRCTN73765130

Single

2215

668

Pan 2021

18-59y

China

KCONVAC

Ⅰ/Ⅱ

ChiCTR2000038804
/ChiCTR2000039462

Double

448

112

Ramasamy 2020

18-55;56-60;≥70y

United Kingdom

ChAdOx1 nCoV-19

Ⅱ/Ⅲ

NCT04400838

Single

460

100

Richmond 2021

18-54y；55-75y

Australia

SCB-2019

Ⅰ

NCT04405908

Double

121

30

Shu 2021

18-59y;
≥60y

China

V-01

Ⅱ

ChiCTR2100045107

Double

360

80

Tanriover 2021

18-59y

Turkey

CoronaVac

Ⅲ

NCT04582344

Double

6650

3568

Toback 2021

18-64y;≥65y

United Kingdom

NVX-CoV2373

Ⅲ

NCT04583995

Single

7020

7019

Voysey 2021

≥18y

The United Kingdom, Brazil, South Africa

ChAdOx1 nCoV-19

Ⅲ

ISRCTN89951424;NCT04324606;NCT04400838;NCT04444674

Single/Double

8597

8181

Wu 2021

≥60y

China

CoronaVac

Ⅰ/Ⅱ

NCT04383574

Double

348

74

Xia 2021

18-59y；≥60y

China

BBIBP-CorV

Ⅰ/Ⅱ

ChiCTR2000032459

Double

480

160

Yang 2021

18-59y

China

ZF2001

Ⅰ/Ⅱ

NCT04445194/NCT04466085

Double

720

160

Zhang 2020

18-59y

China

CoronaVac

Ⅰ/Ⅱ

NCT04352608

Double

96

48

Zhu 2020

≥18y

China

Ad5

Ⅱ

NCT04341389

Double

382

126

studies

Reaction/total     %

RR (95%)

I²

vaccinated

unvaccinated

Total adverse reactions

23

23231/56459

41.15%

10658/29780

35.79%

1.42 [1.23, 1.64]

96%

Systemic adverse reactions

18

17519/45468

38.53%

7000/21532

32.51%

1.26 [1.08, 1.47]

95%

Local adverse reactions  

18

12851/45468

28.26%

4758/21532

22.10%

2.77 [1.68, 4.55]

98%

Total adverse reactions

mRNA vaccines

3

2338/2499

93.56%

1449/2225

65.12%

1.85 [1.34, 2.55]

91%

Adenovirus vector vaccines

2

733/1406

52.13%

135/466

29.0%

1.81 [1.56, 2.10]

0%

Inactivated vaccines

9

14754/36532

40.39%

7637/17884

42.70%

1.05 [0.94, 1.18]

69%

Protein Subunit vaccines

8

4959/13807

36.13%

310/1518

20.42%

1.77 [1.11, 2.83]

94%

Mixed vaccination

1

417/2215

18.83%

123/668

18.41%

1.02 [0.85, 1.23]

/ b

Systemic adverse reactions

mRNA vaccines

3

2012/2499

80.51%

1297/2225

58.29%

1.74 [1.20, 2.53]

86%

Adenovirus vector vaccines

1

106/192

55.21%

6/64

9.38%

3.93 [2.11, 7.29]

/

Inactivated vaccines

8

11527/36085

31.94%

5142/17745

28.95%

1.02 [0.77, 1.36]

97%

Protein Subunit vaccines

6

3766/6698

56.23%

552/1498

36.85%

1.18 [0.85, 1.63]

87%

Local adverse reactions

mRNA vaccines

3

2082/2449

85.01%

506/2225

22.74%

5.30 [2.99, 9.38]

85%

Adenovirus vector vaccines

1

116/192

60.42%

6/64

9.38%

6.44 [2.98, 13.92]

/

Inactivated vaccines

8

6836/36085

18.94%

4017/17745

22.64%

1.86 [1.13, 3.06]

92%

Protein Subunit vaccines

6

3817/6698

56.99%

229/1498

15.29%

2.42 [1.21, 4.81]

95%

Pain

mRNA vaccines

4

3326/4167

79.82%

335/3915

8.56%

14.07 [3.77, 52.53]

98%

Adenovirus vector vaccines

2

317/574

55.23%

15/190

7.89%

6.94 [4.25,11.34]

0%

Inactivated vaccines

9

6234/36532

17.06%

3890/17884

21.75%

1.66 [1.06, 2.57]

91%

Protein Subunit vaccines

7

12230/46270

26.43%

4571/21561

21.20%

1.77 [1.11, 2.83]

94%

Redness

mRNA vaccines

5

2608/6382

40.86%

555/4583

12.11%

4.19 [1.87, 9.41]

98%

Adenovirus vector vaccines

4

776/1679

46.22%

104/610

17.05%

4.36 [1.42, 13.41]

91%

Inactivated vaccines

9

322/36532

0.88%

157/17884

0.88%

0.96 [0.80, 1.17]

0%

Protein Subunit vaccines

7

253/6787

3.73%

6/1518

0.40%

3.54 [0.99, 12.72]

57%

Swelling

mRNA vaccines

4

248/4167

5.95%

30/3915

0.77%

7.56 [5.20, 11.00]

0%

Adenovirus vector vaccines

3

18/655

2.75%

1/270

0.37%

3.51 [0.80, 15.46]

0%

Inactivated vaccines

9

349/36532

0.96%

175/17884

0.98%

0.93 [0.78, 1.12]

0%

Protein Subunit vaccines

7

472/6787

6.95%

9/1518

0.59%

7.86 [4.36, 14.14]

0%

Fever

mRNA vaccines

4

606/4167

14.54%

26/3915

0.66%

21.98 [6.61, 73.02]

81%

Adenovirus vector vaccines

3

128/655

19.54%

12/270

4.44%

3.54 [1.61, 7.79]

9%

Inactivated vaccines

9

782/36532

2.14%

371/17884

2.07%

1.01 [0.90, 1.15]

0%

Protein Subunit vaccines

6

134/6666

2.01%

32/1488

2.15%

1.17 [0.79, 1.72]

0%

Headache

mRNA vaccines

4

2315/4167

55.56%

1270/3915

32.44%

1.75 [1.37, 2.23]

91%

Adenovirus vector vaccines

3

182/655

27.79%

87/270

32.22%

1.69 [0.40, 7.13

94%

Inactivated vaccines

9

4148/36532

11.35%

2000/17884

11.18%

1.03 [0.98, 1.08]

94%

Protein Subunit vaccines

7

1102/6787

16.24%

192/1518

12.56%

1.02 [0.72, 1.46]

63%

Fatigue

mRNA vaccines

4

2477/4167

59.44%

1368/3915

34.94%

1.70 [1.31, 2.20]

93%

Adenovirus vector vaccines

2

204/574

35.54%

27/190

14.21%

2.79 [1.59, 4.92]

32%

Inactivated vaccines

8

665/9596

6.93%

277/4431

6.25%

1.19 [1.04, 1.36]

0%

Protein Subunit vaccines

7

1561/6787

23.00%

251/1518

16.53%

1.12 [0.94, 1.33]

18%

Vomiting

mRNA vaccines

4

370/4167

8.88%

129/3915

3.30%

2.86 [1.51, 5.41]

70%

Adenovirus vector vaccines

2

8/574

1.39%

1/190

0.53%

1.87 [0.33, 10.53]

0%

Inactivated vaccines

9

254/36532

0.70%

56/17884

0.31%

1.89 [1.43, 2.50]

33%

Protein Subunit vaccines

7

353/6787

5.20%

52/1518

3.43%

1.26 [0.95, 1.66]

0%

Grade 3

mRNA vaccines

4

858/4167

20.59%

83/3915

2.12%

6.49 [2.64, 15.96]

86%

Adenovirus vector vaccines

3

81/1598

5.07%

26/530

4.91%

1.81 [0.40, 8.20]

77%

Inactivated vaccines

5

249/34919

0.71%

121/17436

0.69%

0.99 [0.80, 1.23]

0%

Protein Subunit vaccines

5

167/5741

2.91%

21/1286

1.63%

1.60 [0.64, 4.02]

66%

Mixed vaccination

1

71/2215

3.21%

15/668

2.25%

1.43 [0.82, 2.47]

/